Healthcare AI article warns: validation must meet clinical trial standards

This piece captures a growing backlash against “move fast and break things” in clinical AI. The core argument—that decision-support models should be validated as rigorously as drugs or devices—cuts directly against the deployment style we’ve seen in consumer AI, where models ship first and guardrails catch up later. As models begin to recommend treatments, triage patients and influence reimbursement, the cost of silent failure is simply too high.

For AGI, healthcare is a bellwether. If high‑stakes domains converge on expectations of modular architectures, prospective trials and post‑market surveillance, those norms will likely bleed into how we evaluate more general agents. A future AGI system trusted to coordinate care across a hospital or manage a national health system will need traceability, ablation‑style testing and clear failure modes—not just good scores on synthetic benchmarks.

There is a trade‑off: stringent validation slows diffusion. But in practice it may also force the field to invent better evaluation science—standardised endpoints, robust out‑of‑distribution tests, and methods to detect emergent behaviours over long time horizons. Those tools will be invaluable when we’re trying to understand the real‑world behaviour of increasingly general systems, not just medical models.